German pharmaceutical company BioNTech says it has begun testing a potential vaccine for the new coronavirus on volunteers.
BioNTech, which is working with U.S.-based Pfizer, said Wednesday that 12 participants of a clinical trial in Germany have received doses of the vaccine candidate BNT162 since April 23.
Numerous pharmaceutical companies are racing to deliver a vaccine for the virus that has caused a pandemic and led to more than 215,000 deaths worldwide and sickened at least three million people.
BioNTech said in a statement that in a next step, it will begin increasing the dose of BNT162 in a trial involving about 200 participants aged 18 to 55.
The company said it expects to receive regulatory approval to begin trials in the United States soon.